Effect of Concanamycin A on the percentage of mortality in Tax-positive or -negative cells
| Patient . | Tax-negative Cells . | Tax-positive Cells . |
|---|---|---|
| TAN | ||
| −Concanamycin A | 1.0 | 40.0 |
| +Concanamycin A | 4.6 | 18.6 |
| HAW | ||
| −Concanamycin A | 2.0 | 22.0 |
| +Concanamycin A | 3.8 | 12.0 |
| Patient . | Tax-negative Cells . | Tax-positive Cells . |
|---|---|---|
| TAN | ||
| −Concanamycin A | 1.0 | 40.0 |
| +Concanamycin A | 4.6 | 18.6 |
| HAW | ||
| −Concanamycin A | 2.0 | 22.0 |
| +Concanamycin A | 3.8 | 12.0 |
Peripheral blood mononuclear cells were isolated from an asymptomatic carrier (HAW) of the human T-cell leukemia virus type I (HTLV-I) and a patient with HTLV-I-associated myelopathy/tropical spastic paraparesis (TAN), cultivated for 24 hours in the presence (+) or in the absence (−) of 20 nmol/L Concanamycin A, and then processed to perform the concomitant detection of Tax and propidium iodide, used to determine the percentage of mortality as described in “Materials and Methods.”